Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences
September 09 2020 - 7:00AM
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader,
today announced that the company is scheduled to present at the
following virtual investor conferences in September:
- Morgan Stanley 18th Annual Global Healthcare Conference on
September 18, 2020 at 8:45 AM ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
on September 23, 2020 at 9:10 AM ET
Live webcasts of each presentation will be available under "News
& Events" in the Investors & Media section of the company's
website at www.orchard-tx.com. The webcasts will be archived on the
Orchard website following each presentation.
About Orchard
Orchard Therapeutics is a global gene therapy leader dedicated
to transforming the lives of people affected by rare diseases
through the development of innovative, potentially curative gene
therapies. Our ex vivo autologous gene therapy approach harnesses
the power of genetically modified blood stem cells and seeks to
correct the underlying cause of disease in a single administration.
In 2018, Orchard acquired GSK’s rare disease gene therapy
portfolio, which originated from a pioneering collaboration between
GSK and the San Raffaele Telethon Institute for Gene Therapy in
Milan, Italy. Orchard now has one of the deepest and most advanced
gene therapy product candidate pipelines in the industry spanning
multiple therapeutic areas where the disease burden on children,
families and caregivers is immense and current treatment options
are limited or do not exist.
Orchard has its global headquarters in London and U.S.
headquarters in Boston. For more information, please visit
www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About
Orchard
Investors and others should note that Orchard communicates with
its investors and the public using the company website
(www.orchard-tx.com), the investor relations website
(ir.orchard-tx.com), and on social media
(Twitter and LinkedIn), including but not limited to
investor presentations and investor fact sheets, U.S.
Securities and Exchange Commission filings, press releases,
public conference calls and webcasts. The information that Orchard
posts on these channels and websites could be deemed to be material
information. As a result, Orchard encourages investors, the media,
and others interested in Orchard to review the information that is
posted on these channels, including the investor relations website,
on a regular basis. This list of channels may be updated from time
to time on Orchard’s investor relations website and may include
additional social media channels. The contents of Orchard’s website
or these channels, or any other website that may be accessed from
its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Contacts
Investors
Renee LeckDirector, Investor Relations+1
862-242-0764Renee.Leck@orchard-tx.com
Orchard Therapeutics (NASDAQ:ORTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Orchard Therapeutics (NASDAQ:ORTX)
Historical Stock Chart
From Apr 2023 to Apr 2024